BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 35070755)

  • 1. Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments.
    Shi Y; Liu X; Liu J; Zhang D; Liu X; Yue Y; Zhou Q; Gao X; Chen M; Xu Y; Zhao J; Zhong W; Provencio M; Jassem J; Williams TM; Seeber A; Kocher F; Wang M
    Transl Lung Cancer Res; 2021 Dec; 10(12):4477-4493. PubMed ID: 35070755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive Correlation of Peripheral CD8
    Wu K; Xia B; Zhang J; Li X; Yang S; Zhang M; Zhu L; Wang B; Xu X; Ma S; Chen X
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
    Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
    Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
    Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors.
    Bai R; Li L; Chen X; Chen N; Song W; Zhang Y; Lv Z; Han F; Zhao Y; Li W; Cui J
    J Oncol; 2021; 2021():9935076. PubMed ID: 34335763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors.
    Lin X; Chen X; Long X; Zeng C; Zhang Z; Fang W; Xu P
    Respir Res; 2023 Feb; 24(1):64. PubMed ID: 36849947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy.
    Wang H; Zhou F; Zhao C; Cheng L; Zhou C; Qiao M; Li X; Chen X
    Front Immunol; 2022; 13():840313. PubMed ID: 35222434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study.
    Zhang D; Shi Y; Liu X; Liu J; Xu Y; Zhao J; Zhong W; Käsmann L; Hakozaki T; Provencio M; Horita N; Fukuda N; Chen M; Wang M
    Transl Lung Cancer Res; 2022 Jul; 11(7):1420-1433. PubMed ID: 35958331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
    Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
    Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
    Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence.
    Xu H; Feng H; Zhang W; Wei F; Zhou L; Liu L; Zhao Y; Lv Y; Shi X; Zhang J; Ren X
    Exp Cell Res; 2022 Jul; 416(1):113157. PubMed ID: 35427598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
    JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Predictive Model Construction for Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy.
    Gao W; Liu Q; Zhou Y; Yang M; Yu Y
    Technol Cancer Res Treat; 2023; 22():15330338231206705. PubMed ID: 37927008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High level of C-reactive protein as a predictive factor for immune-related adverse events of immune checkpoint inhibitors in non-small cell lung cancer: a retrospective study.
    Onodera R; Chiba S; Nihei S; Fujimura I; Akiyama M; Utsumi Y; Nagashima H; Kudo K; Maemondo M
    J Thorac Dis; 2023 Aug; 15(8):4237-4247. PubMed ID: 37691668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer.
    Huang L; Li L; Zhou Y; Yang Z; Wang M; Gao Y; Yang Y; Yang F; Liu B; Hong X; Chen G
    J Cancer; 2020; 11(24):7137-7145. PubMed ID: 33193876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.
    Sayer MR; Mambetsariev I; Lu KH; Wong CW; Duche A; Beuttler R; Fricke J; Pharoan R; Arvanitis L; Eftekhari Z; Amini A; Koczywas M; Massarelli E; Roosan MR; Salgia R
    Front Oncol; 2023; 13():1064169. PubMed ID: 36860308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
    Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
    World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Miao K; Zhang X; Wang H; Si X; Ni J; Zhong W; Zhao J; Xu Y; Chen M; Pan R; Wang M; Zhang L
    Front Immunol; 2022; 13():912180. PubMed ID: 35844502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.